Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment of Langerhans Cell Histiocytosis and Histiocytic Disorders: A Focus on MAPK Pathway Inhibitors.

Paediatric drugs - 1 Jul 2023

Geerlinks Ashley V, Abla Oussama

Abstract excerpt

Histiocytic disorders are rare diseases defined by the clonal accumulation of a macrophage or dendritic cell origin. These disorders include Langerhans cell histiocytosis, Erdheim-Chester disease, juvenile xanthogranuloma, malignant histiocytoses, and Rosai-Dorfman-Destombes disease. These histiocytic disorders are a diverse group of disorders with different presentations, management, and prognosis. This review...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Erdheim-Chester Disease
Share to Histiocytosis, Langerhans-Cell
Share to Mutation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Prognosis

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 37204611
DOI: 10.1007/s40272-023-00569-8

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment of Langerhans Cell Histiocytosis and Histiocytic Disorders: A Focus on MAPK Pathway Inhibitors.PMID 37204611Read ↗

Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease.Semantic proximity Read ↗

Signaling pathways, microenvironment, and targeted treatments in Langerhans cell histiocytosis.Semantic proximity Read ↗

Biological and clinical significance of somatic mutations in Langerhans cell histiocytosis and related histiocytic neoplastic disorders.Semantic proximity Read ↗

[An overview of histiocytosis].Semantic proximity Read ↗

Langerhans cell histiocytosis: current advances in molecular pathogenesis.Semantic proximity Read ↗

[Updated AWMF Guideline on the Diagnosis and Treatment of Langerhans cell Histiocytosis in Children and Adolescents].Semantic proximity Read ↗

Molecular Pathogenesis of the Histiocytic and Dendritic Cell Neoplasms.Semantic proximity Read ↗

Erdheim-Chester disease: a rapidly evolving disease model.Semantic proximity Read ↗

Erdheim–Chester Disease: Comprehensive Review of Molecular Profiling and Therapeutic AdvancesSemantic proximity Read ↗

[Pathophysiology and treatment of adult Langerhans cell histiocytosis].Semantic proximity Read ↗

Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesisSemantic proximity Read ↗

Molecular characterization of the histiocytoses: Neoplasia of dendritic cells and macrophages.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.